Main description:

This book focuses on putting successful molecular strategies into practice for the treatment of gynecologic cancer. It approaches research into the pathology and treatment of gynecologic oncology from both clinical and experimental perspectives. New insights made possible by the introduction of advanced technologies into the field are presented. This new volume will be necessary reading for clinicians and experimental researchers alike.

Contents:

***completed

________________________________________________________________________________
MOLECULAR PATHOLOGY OF GYNECOLOGIC CANCER

EDITORS : ANTONIO GIORDANO , M.D., Ph.D.
ALESSANDRO BOVICELLI , M.D., Ph.D.
ROBERT J. KURMAN, M.D., Ph.D.

***PREFACE
Alessandro Bovicelli and Giovan Giacomo Giordano, Honorary President of the Italian Tumor Society (SIT)

PART I : INTRODUCTION

***Chapter 1 : The Cell Cycle and the Molecular Biology of Cancer
Giuseppina D'Andrilli, Alessandro Bovicelli and Antonio Giordano
Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, BioLife Science Building, Suite 333, 1900 N 12th Street. Philadelphia, PA, 19122.

This chapter evaluates the molecules that conduct progression through the cell cycle and describes their activities that are linked together to control the process of cell reproduction. In light of these concepts, we believe that cancer is mainly a disease of the cell cycle based on the deregulation of this physiological process. This hypothesis is further elaborated upon and illustrated in the subsequent chapters .

PART II : OVARIAN CANCER :

***Chapter 2 : Ovarian Serous Carcinogenesis-A Proposed Model
Ie-Ming Shih and Robert. J Kurman
Department of Pathology, The Johns Hopkins University School of Medicine, 401 North Broadway, Baltimore, Maryland, 21231-2410, USA.

This chapter discusses the most innovative pathological issues that define ovarian neoplasia. The emphasis is placed on different ovarian pathways of carcinogenesis and progression to advanced disease. Particular focus is directed to borderline disease and its classification.

***Chapter 3 : Molecular Markers in Epithelial Ovarian Cancer.
Pat Morin
Laboratory of Cellular and Molecular Biology, Gerontology Research Center, NationalInstitute on Aging, Building 31, Room 5C27, 31 Center Drive, MSC 2292, Bethesda, MD 20892, morinp@grc.nia.nih.gov

This chapter summarizes the studies which have correlated cancer screening, diagnosis and prognosis with structure and expression profiles of molecular markers. New insights made possible by the utilization of new technologies are discussed. The emphasis is placed on cell cycle regulatory genes . The diversity of cancer types and the value of examining multi-gene profiles is discussed in this chapter.

PART III : ENDOMETRIAL CANCER :

***Chapter 4 : Introduction to Endometrial Cancer.
Richard Zaino
Department of Pathology, Milton S. Hershey Medical Center of Pennsylvania State University, Hershey, Pennsylvania 17033, USA

This chapter discusses the most innovative pathological issues that define endometrial neoplasia . Special focus is placed on pre-neoplastic lesions. The criteria established for distinguishing lesions on the basis of architectural and cytological abnormalities are examined. Differences between simple or complex hyperplasia with or without atypia are also stressed. Histological types of advanced disease and implications for a different course of the disease are examined.

***Chapter 5 : Endometrial Carcinogenesis : An Integrated, Molecular, Histologic and Functional Model of a Dualistic Disease.
Mutter G
Pathology Institute, Brigham and Women's Hospital, 02115 Boston, Massachusetts.
gmutter@rics.bwh.harvard.edu

Among the hormone-related carcinomas, the best understood etiologically is endometrial cancer. The demographic characteristics of the disease as well as the non-demographic risk factors are mainly due to a cumulative exposure of the endometrium to that fraction of estrogen that is unopposed by the influence of progesterone. On the other hand, recent data in the literature defined two distinct pathways of endometrial carcinogenesis an